Neuroendocrine Tumor

P=N/A, N=600, Recruiting, Hospices Civils de Lyon

[203Pb]Pb-VMT-α-NET appears to be a safe and effective SPECT/CT tracer for imaging NETs larger than 1 cm and for normal organ and tumor radiation dosimetry. The chemically matched 203/212Pb theranostic pair offers the potential for a dosimetry-driven personalized treatment paradigm.

Its stability and independence from common confounders make it a valuable complement to calcitonin. The combined assessment of calcitonin and procalcitonin enhances diagnostic performance and should be considered in routine clinical practice.

P3, N=79, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Aug 2026

The determination of affinity was accomplished using microscale thermophoresis (MST). Here, we describe a detailed protocol for the assessment of binding affinities between HIF2α peptides or the entire oxygen-dependent degradation domains of HIFα proteins and PHD2 using MST and propose that this method can be used to assess the potential pathogenicity of novel mutations in HIF2α.

In the NEN cell lines BON-1, QGP-1, and MS-18, we applied cisplatin, etoposide, streptozotocin, 5-fluorouracil, temozolomide, and everolimus- all systemic agents used in highly proliferative NEN. These findings might have an impact on the optimal therapy sequence and patient selection for future CXCR4-targeted approaches. Further, the decreased CXCR4 expression could represent a new mechanism of action of the established drugs Cisplatin, Temozolomide, and Everolimus.

Orthotopic pancreatic implantation of dual-labeled STC-1 cells provides a biologically relevant and pragmatic preclinical platform that closely resembles human PNETs. This model offers valuable utility for investigating PNET biology and evaluating novel therapeutic strategies.

P1/2, N=232, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Recruiting --> Active, not recruiting

ImmunoPET identified &lsqb;89Zr]Zr-DFO-TDI-Y-010 as the top-performing diagnostic tracer, with excellent in vivo biodistribution and tumor-to-background-organ ratios consistently >4. Therapeutic studies with &lsqb;177Lu]Lu-CHX-A"-DTPA-TDI-Y-010 demonstrated strong antitumor effects, significantly improving (P <0.05) overall survival compared with the benchmark clone &lsqb;177Lu]Lu-CHX-A"-DTPA-SC16.56 in two SCLC tumor models (NCI-H82 and Lu149) and achieving comparable overall survival in a NEPC tumor model.

Achieving R0 or R1 resections has been associated with better survival outcomes. The successful implementation of radioguided surgery for NETs requires a multidisciplinary approach, both surgeons and nuclear medicine specialists playing a relevant role, and who must be aware of its prognostic significance.

Recurrent GI bleeding in ZES requires a coordinated approach integrating medical, endoscopic, and surgical therapies. Early recognition is essential to prevent severe complications, and a high index of suspicion is warranted in patients with refractory PUD, chronic diarrhoea, or unexplained GI bleeding.

Approximately 40% of PPGL harbor germline mutations, whereas somatic alterations account for additional subsets. Mutations in SDHx, VHL, RET, NF1, and other susceptibility genes define molecular clusters with distinct signaling pathways and clinical behavior, underscoring the importance of multidisciplinary, lifelong management.